CJC-1295 NO DAC (5mg) + Ipamorelin (5mg) Blend

Research Peptide

CJC-1295 No DAC + Ipamorelin Blend (5mg/5mg) combines two well-researched GH secretagogues in an equal 1:1 ratio. CJC-1295 (No DAC) (Mod GRF 1-29) functions as a short-acting GHRH analog, while Ipamorelin acts as a selective ghrelin mimetic and GHS-R agonist.

Together, in laboratory models, they support research into synergistic GH release mechanisms, pulsatile secretion patterns, and downstream IGF-1 signaling.

Each vial contains 5mg CJC-1295 No DAC and 5mg Ipamorelin provided as a sterile lyophilized blend with ≥99% purity verified by HPLC.

This pre-mixed format simplifies reconstitution and dosing for in vitro assays, cell culture experiments, and small-animal research protocols.

The blend is intended exclusively for in vitro and in vivo laboratory research. It is not intended for human consumption, therapeutic use, or any non-research application.

For research use only. Strictly not for human consumption.

Biochemical Characteristics

CJC-1295 No DAC (Mod GRF 1-29) is a 29-amino-acid GHRH analog with four substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) for enhanced stability and receptor affinity.

Molecular weight: ≈3367 Da

Half-life: ~30 minutes

Ipamorelin is a pentapeptide ghrelin mimetic (Aib-His-D-2-Nal-D-Phe-Lys-NH₂).

Molecular weight: 711.85 Da — Half-life: ~2 hours

The blend is provided as a single lyophilized powder containing equal parts of both peptides in acetate salt form.

This combination allows researchers to study complementary pathways including GHRH receptor activation and selective GHS-R stimulation with minimal off-target endocrine effects.

Research Application

The CJC-1295 (No DAC) + Ipamorelin blend is used in endocrine, metabolic, and aging research to:

• Examine synergistic amplification of pulsatile GH secretion
• Investigate IGF-1 axis dynamics and anabolic/catabolic balance
• Model physiological GH rhythm without prolonged receptor desensitization
• Study effects on body composition, lipolysis, and protein synthesis in laboratory systems
• Evaluate potential neuroprotective or regenerative outcomes linked to GH/IGF-1 signaling
• Improve workflow efficiency in multi-dose or comparative research protocols

Mechanism of Action

CJC-1295 (No DAC) binds to pituitary GHRH receptors and activates Gs-protein coupled signaling pathways.

This increases cyclic AMP, activates protein kinase A, and stimulates pulsatile GH transcription and release.

Its short half-life (~30 minutes) mimics natural physiological GHRH pulses without continuous stimulation.

Ipamorelin selectively activates the ghrelin receptor (GHS-R1a), triggering rapid GH pulses through calcium mobilization and Gq-protein signaling.

Its receptor selectivity minimizes stimulation of prolactin, cortisol, or ACTH pathways.

CJC-1295 enhances GH pulse amplitude, while Ipamorelin increases pulse frequency, enabling investigation of synergistic GH/IGF-1 responses.

Preclinical Research Summary

Preclinical and early clinical literature indicates enhanced GH secretion profiles when both peptides are combined.

In vitro pituitary studies demonstrate higher GH release compared to individual peptide exposure.

Rodent studies show increased IGF-1 levels while maintaining physiological pulsatility, alongside improvements in lean mass and metabolic markers.

Short-acting CJC-1295 avoids prolonged GH elevation associated with DAC variants.

Ipamorelin’s selective activity reduces unwanted endocrine effects.

Applications under investigation include wound healing, sarcopenia, metabolic regulation, and age-related endocrine decline.

There is currently no approved human therapeutic use; all findings remain investigational.

Form and Analytical Testing

Form: Sterile lyophilized powder blend (5mg + 5mg) Purity: ≥99% (HPLC verified) Identity: Confirmed by mass spectrometry Endotoxin: <0.1 EU/μg Solubility: Excellent in bacteriostatic water Appearance: White to off-white cake Storage: 2–8°C, protected from light and moisture Reconstitution: Sterile bacteriostatic water under aseptic conditions Stability: 24–36 months sealed; 4–6 weeks after reconstitution

All batches undergo third-party analytical testing for purity, identity, and contaminant screening.

RUO Disclaimer

The CJC-1295 No DAC + Ipamorelin Blend (5mg/5mg) is an investigational compound intended solely for laboratory research and animal studies.

It is not approved by the FDA, EMA, or any regulatory authority for human therapeutic or diagnostic use.

Preclinical findings do not predict human outcomes, and no safety or efficacy claims are made.

Handle only within qualified research facilities under institutional biosafety oversight. Not for human or veterinary consumption.